Metafora partner wugen to present data supporting clinical development of wu-nk-101 for relapsed / refractory aml at the american society of hematology's (ash) 64th annual meeting

Paris, france & new orleans, la.--( business wire )--metafora biosystems announces that its partner wugen presented data supporting clinical development of wu-nk-101 yesterday for relapsed / refractory aml at the american society of hematology's (ash) 64th annual meeting. metafora worked with the wugen team to characterize wugen's drug candidate wu-nk-01, a novel, off-the-shelf therapy for aml, which wugen expects to advance to the clinic.
ASH Ratings Summary
ASH Quant Ranking